Overview

CC-42344 Phase 1 Safety and PK Study in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.
Phase:
Phase 1
Details
Lead Sponsor:
Cocrystal Pharma, Inc.
Collaborators:
Cocrystal Pharma Australia Pty Ltd.
Linear Clinical Research